Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor

Journal of Neuroimmunology

Volumn 104, Issue 2, 2000, Pages 124-132

  Papanastasiou, Danai ^a   Poulas, Konstantinos ^a   Kokla, Anna ^a   Tzartos, Socrates J ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

Acetylcholine receptor; Experimental autoimmune myasthenia gravis; Fab; Main immunogenic region; Monoclonal antibodies

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENIC MODULATION; ARTICLE; CONTROLLED STUDY; FEMALE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; TIME FACTORS;

EID: 0034193962     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00259-3     Document Type: Article

References (43)

1. Buchegger F., Haskell C.M., Schreyer M., Scazziga B.R., Randin S., Carrel S., Mach J.P. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J. Exp. Med. 158:1983;413-427.
2. Drachman D.B. Myasthenia gravis. Rose N.R., Mackay I.R. The Autoimmune Diseases. 1998;637-662 Academic Press, San Diego, CA.
3. Drachman D.B., Angus C.W., Adams R.N., Michelson J.D., Hoffman G.J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. New Engl. J. Med. 298:1978;1116-1122.
4. Gomez C.M., Richman D.P. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J. Immunol. 135:1985;234-241.
5. Heidenreich F., Vincent A., Roberts A., Newsom-Davis J. Epitopes on human acetylcholine receptor defined by monoclonal antibodies and myasthenia gravis sera. Autoimmunity. 1:1988;285-297.
6. Hong G., Bazin-Redureau M.I., Scherrmann J.G. Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. J. Pharm. Sci. 88:1999;147-153.
7. Kitamura K., Takahashi T., Yamaguchi T., Noguchi A., Noguchi A., Takashina K., Tsurumi H., Inagake M., Toyokuni T., Hakomori S. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res. 51:1991;4310-4315.
8. Kontou M., Vatzaki E.H., Kokla A., Acharya K.R., Oikonomakos N.G., Tzartos S.J. Characterisation, crystallisation and preliminary X-ray diffraction analysis of a Fab fragment of a rat monoclonal antibody with very high affinity for the human muscle acetylcholine receptor. FEBS Lett. 389:1996;195-198.
9. Lennon V.A., Lambert E.H. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptor. Nature. 285:1980;238-240.
10. Lennon V.A., Griesmann G.E. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis. Neurology. 39:1989;1069-1076.
11. Lennon V.A., Lindstrom J.M., Seybold M.E. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141:1975;1365-1375.
12. Lindstrom J., Einarson B., Tzartos S.J. Production and assay of antibodies to acetylcholine receptor. Methods Enzymol. 74:1981;432-460.
13. Lindstrom J., Shelton D., Fugii Y. Myasthenia gravis. Adv. Immunol. 42:1988;233-284.
14. Lindstrom J.M., Engel A.G., Seybold M.E., Lennon V.A., Lambert E.H. Pathological mechanisms in experimental autoimmune myasthenia gravis. II Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J. Exp. Med. 144:1976;739-753.
15. Loutrari H., Kokla A., Tzartos S.J. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur. J. Immunol. 22:1992;2449-2452.
16. Luther M.A., Schoepfer R., Whiting P., Casey B., Blatt Y., Montal M.S., Montal M., Lindstrom J. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J. Neurosci. 9:1989;1082-1096.
17. Mamalaki A., Trakas N., Tzartos S.J. Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur. J. Immunol. 23:1993;1839-1845.
18. Miyazawa A., Fujiyoshi Y., Stowell M., Unwin N. Nicotinic acetylcholine receptor at 4.6 Å resolution: transverse tunnels in the channel wall. J. Mol. Biol. 288:1999;765-786.
19. Paige A.G., Whitcomb K.L., Liu J., Kinstler O. Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol. Pharm. Res. 12:1995;1883-1888.
20. Papanastasiou D., Mamalaki A., Eliopoulos E., Poulas K., Liolitsas C., Tzartos S.J. Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor. J. Neuroimmunol. 94:1999;182-195.
21. Patrick J., Lindstrom J.L. Autoimmune response to acetylcholine receptors. Science. 180:1973;871-872.
22. Pedley R.B., Boden J.A., Boden R., Begent R.H., Turner A., Haines A.M., King D.J. The potential for enhanced tumour localisation by poly(ethyleneglycol) modification of anti-CEA antibody. Br. J. Cancer. 70:1994;1126-1130.
23. Porath J., Flodin M. Gel filtration: a method for desalting and group separation. Nature. 183:1959;1657-1659.
24. Poznansky M.J., Halford J., Taylor D. Growth hormone-albumin conjugates. Reduced renal toxicity and altered plasma clearance. FEBS Lett. 239:1988;18-22.
25. Sophianos D., Tzartos S.J. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against degradation caused by myasthenic sera. J. Autoimmun. 2:1989;777-789.
26. Souroujon M.C., Fuchs S. Experimental autoimmune myasthenia gravis. Lefkovits I. Immunology Methods Manual. 1997;1763-1773 Academic Press.
27. Toyka K.V., Drachman D.B., Pestronk A., Kao I. Myasthenia gravis: passive transfer from man to mouse. Science. 190:1975;397-399.
28. Toyka K.V., Lowenadler B., Heininger K., Besinger U.A., Birnberger K.L., Fateh-Moghadam A., Heilbronn E. Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG. J. Neurol. Neurosurg. Psychiatry. 43:1980;836-840.
29. Tsantili P., Tzartos S.J., Mamalaki A. High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor. J. Neuroimmunol. 94:1999;15-27.
30. Tzartos S.J., Seybold M., Lindstrom J. Specificities of antibodies to acetylcholine receptor in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 79:1982;188-192.
31. Tzartos S.J., Sophianos D., Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J. Immunol. 134:1985;2343-2349.
32. Tzartos S.J., Rand D.E., Einarson B.E., Lindstrom J.M. Mapping of surface structures of Electrophorus acetylcholine receptor using monoclonal antibodies. J. Biol. Chem. 256:1981;8635-8645.
33. Tzartos S.J., Langeberg L., Hochschwender S., Lindstrom J. Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor. FEBS Lett. 158:1983;116-118.
34. Tzartos S.J., Hochschwender S., Vasquez P., Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J. Neuroimmunol. 15:1987;185-194.
35. Tzartos S.J., Kokla A., Walgrave S., Conti-Tronconi B. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the α-subunit. Proc. Natl Acad. Sci. USA. 85:1988;2899-2903.
36. Tzartos S.J., Barkas T., Cung M.T., Mamalaki A., Marraud M., Orlewski P., Papanastasiou D., Sakarellos C., Sakarellos Daitsiotis M., Tsantili P., Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163:1998;89-120.
37. Vatzaki E.H., Acharya K.R., Oikonomakos N.G., Tzartos S.J. Crystallization and preliminary crystallographic study of an Fab fragment of a pathogenic rat monoclonal antibody against the nicotinic acetylcholine receptor. Protein Sci. 2:1993;1770-1772.
38. Vincent A. Experimental autoimmune myasthenia gravis. Cohen I., Miller A. Autoimmune Disease Models. A Guidebook. 1994;83-106 Academic Press, Orlando, FL.
39. Waldmann T.A. Rosenoer V.M., Oratz M., Rothschild M.A. Albumin Structure, Function and Uses. 1977;255-273 Pergamon Press, Oxford.
40. Wolfensohn S., Lloyd M. Biological data. Handbook of Laboratory Animal Management and Welfare. 1994;114-142 Oxford University Press, Oxford.
41. Yeh P., Landais D., Lemaitre M., Maury I., Crenne J.Y., Becquart J., Murry-Brelier A., Boucher F., Montay G., Fleer R. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc. Natl. Acad. Sci. USA. 89:1992;1904-1908.
42. Zhang Y., Tzartos S.J. B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: autoantibody mediated up-regulation of the response of acetylcholine receptor-specific T lymphocytes. Immunology. 77:1992;571-576.
43. Zhang Y., Tzartos S.J., Schalke B.C., Melms A., Wekerle H. Interaction between AChR-specific T- and B-line lymphocytes: antigen presentation by B hybridoma cells and the enhancing effect of monoclonal antibodies on T-cell activation. Ann. NY Acad. Sci. 505:1987;71-81.